IP Library Granted Patent US 8,217,175
Granted Patent B2
US 8,217,175 · App. 12/532,410 · Granted Jul 10, 2012

Preparation of oxymorphone from oripavine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,217,175
App. No.
12/532,410
Granted
Jul 10, 2012
Kind
B2
Abstract

An improved method for the preparation of oxymorphone from oripavine is provided. Oripavine is oxidized to form 14-hydroxymorphinone after which the oxidation reaction is quenched to prevent the formation of 1-1′-dimer side products. The 14-hydroxymorphinone is then reduced, typically by catalytic hydrogenation to form oxymorphone. The inventive method disclosed is further applicable to the production of morphinan derivatives.

Claims (38)

1. A method comprising:

a) oxidizing at least one Formula I compound with a peroxyacid oxidizing agent to form an oxidation reaction mixture comprising at least one Formula II compound and Formula II-NO compound;

b) quenching the oxidation reaction mixture by removing an excess portion of the oxidizing agent, wherein the excess portion of the oxidizing agent is oxidizing agent that does not react with the Formula I compound; and

c) reducing the Formula II compound and Formula II-NO compound with a reducing agent to form at least one Formula III compound,

wherein R 1 , R 2 and R 3 are independently selected from H, benzyl, 1-8 carbon alkane sulfonyl, p-tosyl, an alkyl group of 1-20 carbons, and a substituted alkyl group, wherein the alkyl group is substituted with a cyclic alkyl group, a phenyl, substituted phenyl, 1-8 carbon alkoxyl or phenoxyl groups.

2. The method of claim 1 wherein the Formula III compound formed represents greater than an 80% yield.

3. The method of claim 1 wherein the Formula III compound formed represents greater than a 90% yield.

4. The method of claim 1 wherein the Formula III compound formed represents greater than a 95% yield.

5. The method of claim 1 wherein the oxidizing agent includes at least one peroxyacid of the formula RCO 3 H, wherein R is H, an alkyl group of 1-20 carbons or an aryl group.

6. The method of claim 5 wherein the at least one peroxyacid is selected from the group consisting of HCO 3 H, CH 3 CO 3 H, C 6 H 4 CO 3 H, m-CIC 6 H 4 CO 3 H and mixtures thereof.

7. The method of claim 1 wherein the excess oxidizing agent is removed by a method selected from the group consisting of addition of at least one neutralizing agent, electric reduction, thermo-decomposition of the oxidizing agent and a combination thereof.

8. The method of claim 7 wherein the neutralizing agent is selected from the group consisting of H 2 C 2 O 4 , hypophosphorous acid, formic acid, citric acid, ascorbic acid, NaNO 2 , NaS 2 O 4 , Na 2 SO 3 salts of hydrazine, R 8 CHO, wherein R 8 is selected from H, alkyl of 1-20 carbons, or a phenyl or substituted phenyl group, sulfur dioxide, sodium hydrosulfite, formaldehyde sulfoxylate, diimide, hydrazine, hypophosphorous, triphenylphosphine and mixtures thereof.

9. The method of claim 1 wherein the reducing agent is hydrogen in the presence of a transition metal catalyst.

10. The method of claim 9 wherein the transition metal catalyst is selected from the group consisting of Pd/C, Pt/C, Ru/C, Rh/C, Ir/C, Ni/C, PtO 2 , Raney Ni, Wilkinson's Catalyst and mixtures thereof.

11. The method of claim 1 wherein the method is accomplished in a single reaction vessel without isolating the Formula II compound.

12. A method comprising:

a) oxidizing a Formula I compound with at least one peroxyacid of the formula RCO 3 H, wherein R is H, an alkyl group of 1-20 carbons or an aryl group, to form an oxidation reaction mixture comprising a Formula II compound and a Formula II-NO compound;

b) quenching the oxidation reaction mixture by neutralizing an excess portion of the peroxyacid of the formula RCO 3 H with at least one neutralizing agent to form RCO 2 H, wherein the excess portion of the peroxyacid is peroxyacid that does not react with the Formula I compound; and

c) catalytically reducing the Formula II compound and the Formula II-NO compound with hydrogen in the presence of a transition metal catalyst to form a Formula III compound,

wherein R 1 , R 2 and R 3 are independently selected from H, benzyl, 1-8 carbon alkane sulfonyl, p-tosyl, an alkyl group of 1-20 carbons, and a substituted alkyl group, wherein the alkyl group is substituted with a cyclic alkyl group, a phenyl, substituted phenyl, 1-8 carbon alkoxyl or phenoxyl groups.

13. The method of claim 12 wherein the Formula III compound formed represents greater than an 80% yield.

14. The method of claim 12 wherein the Formula III compound formed represents greater than a 90% yield.

15. The method of claim 12 wherein the Formula III compound formed represents greater than a 95% yield.

16. The method of claim 12 wherein the at least one peroxyacid includes a peroxyacid selected from the group consisting of HCO 3 H, CH 3 CO 3 H, C 6 H 4 CO 3 H, m-CIC 6 H 4 CO 3 H and mixtures thereof.

17. The method of claim 12 wherein the neutralizing agent is selected from the group consisting of H 2 C 2 O 4 , hypophosphorous acid, formic acid, citric acid, ascorbic acid, NaNO 2 , NaS 2 O 4 , Na 2 SO 3 , salts of hydrazine, R 8 CHO, wherein R 8 is selected from H, alkyl of 1-20 carbons, or a phenyl or substituted phenyl group, sulfur dioxide, sodium hydrosulfite, formaldehyde sulfoxylate, diimide, hydrazine, hypophosphorous, triphenylphosphine and mixtures thereof.

18. The method of claim 12 wherein the at least one transition metal catalyst is selected from the group consisting of Pd/C, Pt/C, Ru/C, Rh/C, Ir/C and Ni/C, Pt/O 2 , Raney Ni, Wilkinson's Catalyst and mixtures thereof.

19. The method of claim 12 wherein the method is accomplished in a single reaction vessel without isolation of the Formula II compound.

20. A method for producing oxymorphone comprising:

a) oxidizing oripavine with a peroxyacid acid RCO 3 H, wherein R is H, an alkyl group or an aryl group, to form an oxidation reaction mixture comprising 14-hydroxymorphinone and 14-hydroxymorphinone N-oxide;

b) quenching the oxidation reaction mixture by neutralizing an excess portion of the peroxyacid with a neutralizing agent, wherein the excess portion of the peroxyacid is peroxyacid that does not react with the oripavine; and

c) catalytically hydrogenating the 14-hydroxymorphinone and 14-hydroxymorphinone N-oxide with a reducing agent to form oxymorphone.

21. The method of claim 20 wherein the oxymorphone formed represents greater than an 80% yield.

22. The method of claim 20 wherein the oxymorphone formed represents greater than a 90% yield.

23. The method of claim 20 wherein the oxymorphone formed represents greater than a 95% yield.

24. The method of claim 20 wherein the peroxyacid includes a peroxyacid acid selected from the group consisting of HCO 3 H, CH 3 CO 3 H, C 6 H 4 CO 3 H, m-CIC 6 H 4 CO 3 H and mixtures thereof.

25. The method of claim 20 wherein the neutralizing agent is selected from the group consisting of H 2 C 2 O 4 , hypophosphorous acid, formic acid, citric acid, ascorbic acid, NaNO 2 , NaS 2 O 4 , Na 2 SO 3 , salts of hydrazine, R 8 CHO, wherein R 8 is selected from H, alkyl of 1-20 carbons, or a phenyl or substituted phenyl group, sulfur dioxide, sodium hydrosulfite, formaldehyde sulfoxylate, diimide, hydrazine, hypophosphorous, triphenylphosphine and mixtures thereof.

26. The method of claim 20 wherein the reducing agent is hydrogen in the presence of a transition metal catalyst selected from the group consisting of Pd/C, Pt/C, Ru/C, Rh/C, WC, Ni/C, PtO 2 , Raney Ni, Wilkinson's Catalyst and mixtures thereof.

27. The method of claim 20 wherein the method is accomplished in a single reaction vessel without isolating the 14-hydroxymorphinone.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2009
From: WANG, PETER X.; JIANG, TAO; CANTRELL, GARY L.; BERBERICH, DAVID W.
To: MALLINCKRODT INC.
Reel/Frame 023261/0434 →